| Cash Flow | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 23,100 | -18,600 | 154,100 | 207,700 |
| Depreciation and amortization | 343,800 | 171,100 | 563,100 | 376,300 |
| Deferred income taxes | 2,300 | -3,000 | -125,800 | -49,700 |
| Share-based compensation expense related to equity incentive plans | 114,500 | 52,900 | 139,700 | 90,300 |
| Loss on settlement of debt | - | - | -300 | 0 |
| Amortization of debt discount | 6,700 | 1,400 | 51,600 | 28,100 |
| Amortization of debt issuance costs | 2,700 | 1,400 | 6,100 | 4,300 |
| Impairment of intangible assets | 2,500 | 2,200 | 0 | 0 |
| Other | 4,200 | -600 | -45,500 | -24,300 |
| (increase) decrease in accounts receivable | 55,900 | 75,800 | -286,500 | -99,400 |
| Decrease (increase) in inventories | -201,000 | -125,000 | 35,100 | 18,300 |
| Decrease in accounts payable and accrued liabilities | -26,000 | 27,600 | -236,600 | -182,300 |
| Change in other assets and liabilities | 75,800 | 3,400 | 72,700 | 50,000 |
| Change in income tax payable | -179,400 | -4,600 | 6,500 | -60,800 |
| Net cash provided by operating activities | 363,700 | 275,600 | 692,200 | 420,700 |
| Other investing | -1,300 | - | -2,400 | -2,400 |
| Proceeds from capital-related government incentives | 5,100 | 4,800 | 100 | 100 |
| Investments in other assets | 50,900 | 23,800 | 122,500 | 98,500 |
| Capital expenditures | 54,400 | 17,900 | 111,800 | 93,700 |
| Net cash used in investing activities | -98,900 | -36,900 | -231,800 | -189,700 |
| Proceeds from borrowings on revolving credit facility | - | - | 0 | 0 |
| Proceeds from borrowings on 2025 term loan facility | - | - | 0 | 0 |
| Repayments of 2025 term loan facility | - | - | 750,000 | - |
| Proceeds from issuance of commercial paper | 1,588,400 | 0 | 10,567,100 | 6,354,200 |
| Repayments of commercial paper | 650,100 | 174,100 | 10,630,900 | 6,170,600 |
| Proceeds from issuance of senior notes | - | - | 1,992,200 | - |
| Repayment of senior notes | 1,200,000 | - | 1,000,000 | 1,000,000 |
| Proceeds from issuance of convertible debt | 0 | 0 | 1,250,000 | 1,250,000 |
| Payments on settlement of convertible debt | - | - | 668,500 | 0 |
| Deferred financing costs | 0 | 0 | 18,000 | 16,500 |
| Purchase of capped call options | 0 | 0 | 105,000 | 105,000 |
| Proceeds from sale of common stock | 30,300 | 12,400 | 45,400 | 33,600 |
| Tax payments related to shares withheld for vested rsus | 20,000 | 8,400 | 45,000 | 33,200 |
| Repurchase of common stock | 0 | 0 | 96,500 | 90,000 |
| Payment of cash dividends on series a preferred stock | 52,900 | 25,100 | - | - |
| Payment of cash dividends | - | - | 730,900 | 486,300 |
| Payment of cash dividends on common stock | 491,300 | 245,500 | - | - |
| Capital lease payments | 800 | 400 | 1,200 | 800 |
| Other financing | -3,300 | -2,800 | -2,800 | - |
| Net cash used in financing activities | -799,700 | -443,900 | -194,100 | -264,600 |
| Net decrease in cash and cash equivalents | -534,900 | -205,200 | 266,300 | -33,600 |
| Cash and cash equivalents at beginning of period | 771,700 | 771,700 | 319,700 | 319,700 |
| Cash and cash equivalents at end of period | 236,800 | 566,500 | 586,000 | 286,100 |
MICROCHIP TECHNOLOGY INC (MCHPP)
MICROCHIP TECHNOLOGY INC (MCHPP)